Current and Emerging First-line Therapies in Renal Clear-cell Cancer

Theodoros Tegos

ISBN 10: 6200463115 / ISBN 13: 9786200463111

Editore: LAP LAMBERT Academic Publishing Nov 2019, 2019

Riguardo questo articolo

Neuware -Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently underway. Combinations of pembrolizumab/axitinib, avelumab/axitinib, atezolizumab/bevacizumab and pembrolizumab/lenvatinib seem to introduce the mccRCC therapy in a new auspicious era.Books on Demand GmbH, Überseering 33, 22297 Hamburg 52 pp. Englisch.

Codice articolo 9786200463111

Dati bibliografici

• Titolo: Current and Emerging First-line Therapies in Renal Clear-cell Cancer
• Editore: LAP LAMBERT Academic Publishing Nov 2019
• Data di pubblicazione: 2019
• Lingua: Inglese
• ISBN 10: 6200463115
• ISBN 13: 9786200463111
• Rilegatura: Taschenbuch
• Condizione: Neu
• Dimensioni: 220 L x 150 A x 4 P (millimetri) 220 millimetri di larghezza per 150 millimetri di altezza per 4 millimetri di profondità
• Peso: 96 grammi

Descrizione articolo

Riassunto

Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently underway. Combinations of pembrolizumab/axitinib, avelumab/axitinib, atezolizumab/bevacizumab and pembrolizumab/lenvatinib seem to introduce the mccRCC therapy in a new auspicious era.